#BEGIN_DRUGCARD DB00649

# AHFS_Codes:
08:18.08.20

# ATC_Codes:
J05AF04

# Absorption:
Following oral administration, stavudine is rapidly absorbed (bioavailability is 68-104%).

# Biotransformation:
Phosphorylated intracellularly to stavudine triphosphate, the active substrate for HIV-reverse transcriptase.

# Brand_Mixtures:
Not Available

# Brand_Names:
Zerit
Zerit XR
Zerut XR

# CAS_Registry_Number:
3056-17-5

# ChEBI_ID:
Not Available

# Chemical_Formula:
C10H12N2O4

# Chemical_IUPAC_Name:
1-[(2R,5S)-5-(hydroxymethyl)-2,5-dihydrofuran-2-yl]-5-methyl-1,2,3,4-tetrahydropyrimidine-2,4-dione

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
2216094

# Description:
A dideoxynucleoside analog that inhibits reverse transcriptase and has in vitro activity against HIV. [PubChem]

# Dosage_Forms:
Capsule	Oral

# Drug_Category:
Anti-HIV Agents
Antimetabolites
Nucleoside and Nucleotide Reverse Transcriptase Inhibitors
Reverse Transcriptase Inhibitors

# Drug_Interactions:
Zidovudine	Zidovudine may decrease the efficacy of stavudine. Concomitant therapy should be avoided.

# Drug_Reference:
Not Available

# Drug_Type:
Approved
Investigational
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
-0.72

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
5-10 g/100 mL at 21 °C

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
Stavudine

# HET_ID:
Not Available

# Half_Life:
0.8-1.5 hours (in adults)

# InChI_Identifier:
InChI=1S/C10H12N2O4/c1-6-4-12(10(15)11-9(6)14)8-3-2-7(5-13)16-8/h2-4,7-8,13H,5H2,1H3,(H,11,14,15)/t7-,8+/m0/s1

# InChI_Key:
InChIKey=XNKLLVCARDGLGL-JGVFFNPUSA-N

# Indication:
For the treatment of human immunovirus (HIV) infections.

# KEGG_Compound_ID:
C07312

# KEGG_Drug_ID:
D00445

# LIMS_Drug_ID:
649

# Mechanism_Of_Action:
Stavudine inhibits the activity of HIV-1 reverse transcriptase (RT) both by competing with the natural substrate dGTP and by its incorporation into viral DNA.

# Melting_Point:
159-160 °C

# Molecular_Weight_Avg:
224.2133

# Molecular_Weight_Mono:
224.079706882

# Organisms_Affected:
Human Immunodeficiency Virus

# PDB_Experimental_ID:
Not Available

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/zer1496.shtml

# Pathways:
Not Available

# PharmGKB_ID:
PA451494

# Pharmacology:
Stavudine is a nucleoside reverse transcriptase inhibitor (NRTI) with activity against Human Immunodeficiency Virus Type 1 (HIV-1). Stavudine is phosphorylated to active metabolites that compete for incorporation into viral DNA. They inhibit the HIV reverse transcriptase enzyme competitively and act as a chain terminator of DNA synthesis. The lack of a 3'-OH group in the incorporated nucleoside analogue prevents the formation of the 5' to 3' phosphodiester linkage essential for DNA chain elongation, and therefore, the viral DNA growth is terminated.

# Predicted_LogP_Hydrophobicity:
-0.73

# Predicted_LogS:
-0.74

# Predicted_Water_Solubility:
4.05e+01 g/l

# Primary_Accession_No:
DB00649

# Protein_Binding:
Negligible

# PubChem_Compound_ID:
18283

# PubChem_Substance_ID:
46506943

# RxList_Link:
http://www.rxlist.com/cgi/generic/stavudin.htm

# Salts:
Not Available

# Secondary_Accession_No:
APRD00440

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
CC1=CN([C@@H]2O[C@H](CO)C=C2)C(=O)NC1=O

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
2',3'-Didehydro-3'-deoxythimidine
3'-Deoxy-2'-thymidinene
Estavudina [INN-Spanish]
STV
Sanilvudine
Stavudine [Usan:Ban:Inn]
Stavudinum [INN-Latin]

# Synthesis_Reference:
Not Available

# Toxicity:
Side effects include peripheral neuropathy tingling, burning, numbness, or pain in the hands or feet), fatal lactic acidosis has been reported in patients treated with stavudine (ZERIT) in combination with other antiretroviral agents, severe liver enlargement, inflammation (pain and swelling) of the liver, and liver failure.

# Update_Date:
2013-02-08 16:19:31 -0700

# Wikipedia_Link:
http://en.wikipedia.org/wiki/Stavudine

# pKa_Isoelectric_Point:
Not Available

# Drug_Target_1_Cellular_Location:
Not Available

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
15183338	Goldschmidt V, Marquet R: Primer unblocking by HIV-1 reverse transcriptase and resistance to nucleoside RT inhibitors (NRTIs). Int J Biochem Cell Biol. 2004 Sep;36(9):1687-705.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
Not Available

# Drug_Target_1_GenBank_ID_Gene:
Not Available

# Drug_Target_1_GenBank_ID_Protein:
Not Available

# Drug_Target_1_GeneCard_ID:
Not Available

# Drug_Target_1_Gene_Name:
Not Available

# Drug_Target_1_Gene_Sequence:
Not Available

# Drug_Target_1_General_Function:
Not Available

# Drug_Target_1_General_References:
Not Available

# Drug_Target_1_HGNC_ID:
Not Available

# Drug_Target_1_HPRD_ID:
Not Available

# Drug_Target_1_ID:
7243

# Drug_Target_1_Locus:
Not Available

# Drug_Target_1_Molecular_Weight:
Not Available

# Drug_Target_1_Name:
Reverse transcriptase

# Drug_Target_1_Number_of_Residues:
0

# Drug_Target_1_PDB_ID:
Not Available

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
Not Available

# Drug_Target_1_Protein_Sequence:
Not Available

# Drug_Target_1_Reaction:
Not Available

# Drug_Target_1_Signals:
Not Available

# Drug_Target_1_Specific_Function:
Not Available

# Drug_Target_1_SwissProt_ID:
Q5DNL9

# Drug_Target_1_SwissProt_Name:
Not Available

# Drug_Target_1_Synonyms:
Not Available

# Drug_Target_1_Theoretical_pI:
Not Available

# Drug_Target_1_Transmembrane_Regions:
Not Available

#END_DRUGCARD DB00649
